Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.06 | N/A | -18.65% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.06 | N/A | -18.65% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market conditions impacting growth. They did not provide any forward-looking guidance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability.
PTC Therapeutics reported a larger-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue figures and guidance may leave investors uncertain about the company's future performance. Overall, the market reacted negatively, reflecting concerns about the company's current trajectory and profitability challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
T-MOBILE US INC
Oct 28, 2019